Secondary prevention simulator — прихильність до модифікації факторів ризику інсульту: medication and lifestyle adherence driving cumulative recurrent-stroke risk reduction
Roughly 90% of stroke risk worldwide is attributable to a compact set of modifiable factors. After an index stroke or TIA, systematic screening for hypertension, dyslipidemia, diabetes, smoking, sedentary behavior, obesity, atrial fibrillation, and poor diet quality forms the foundation of secondary prevention — because unlike age or prior stroke history, every one of these factors can be acted upon.
The INTERSTROKE case-control study (32 countries, >13,000 stroke cases) established that ten factors explain roughly 90% of population-attributable stroke risk. This simulator focuses on the eight most actionable in a secondary-prevention clinic visit:
• Hypertension — the single strongest modifiable factor; population-attributable risk ~48% for all stroke • Hyperlipidemia — elevated LDL-C and ApoB accelerate large-artery atherosclerosis and plaque rupture • Diabetes mellitus / insulin resistance — roughly doubles ischemic stroke risk and worsens post-stroke outcomes • Current smoking — approximately doubles stroke risk via endothelial injury, prothrombotic state, and accelerated atherosclerosis • Sedentary lifestyle — physical inactivity independently raises risk and compounds every other factor • Obesity / abdominal adiposity — waist-hip ratio correlates more tightly with stroke risk than BMI alone • Atrial fibrillation — raises ischemic stroke risk roughly five-fold and is the dominant cause of cardioembolic stroke • Diet quality — low fruit/vegetable/fiber intake and high sodium intake independently elevate risk
Each factor is not screened once and forgotten — it is re-measured at every follow-up because control (not just diagnosis) is what changes outcomes.
A patient with hypertension, diabetes, and smoking simultaneously does not have three additive risks — the factors interact synergistically, multiplying rather than summing recurrent stroke risk. This is why comprehensive multi-factor control outperforms optimizing any single factor in isolation.
A patient who has already had a stroke or TIA carries a fundamentally different risk profile than a primary-prevention patient: recurrence risk is front-loaded, with the highest hazard in the first 90 days (up to 10–15% recurrence) and remaining elevated for years thereafter.
This compresses the screening and treatment timeline. Rather than the gradual risk-factor optimization typical of primary prevention, post-stroke protocols mandate:
• Same-admission screening: lipid panel, HbA1c, 24-hour or extended (14–30 day) ECG/Holter monitoring for occult AFib, carotid imaging • Immediate statin initiation regardless of baseline LDL in most ischemic strokes (high-intensity statin per AHA/ASA guidelines) • Blood pressure target individualized but generally <130/80 mmHg after the acute phase • Structured discharge counseling on smoking cessation, diet, and activity — the "teachable moment" immediately post-event has measurably higher uptake than counseling offered later
Four drug classes carry the strongest secondary-prevention evidence: high-intensity statins, antihypertensive titration to target, glycemic control agents for diabetic patients, and anticoagulation for atrial fibrillation. Each has robust trial-level relative risk reduction data — but that benefit is only realized at the adherence rate patients actually achieve, which is why the medication-adherence slider drives this stage.
Statin therapy: High-intensity statins (atorvastatin 40–80mg, rosuvastatin 20–40mg) targeting LDL-C <70 mg/dL (or <55 mg/dL in very-high-risk patients) reduce recurrent stroke risk by roughly 30% (SPARCL trial) largely independent of baseline cholesterol, through plaque stabilization and anti-inflammatory effects beyond lipid lowering alone.
Antihypertensive titration: Blood pressure is the single highest-yield target. The PROGRESS trial family demonstrated that each 10 mmHg reduction in systolic pressure lowers recurrent stroke risk by roughly 27%. Combination therapy (ACE inhibitor/ARB + diuretic or calcium channel blocker) is typically required to reach target.
Glycemic control: For patients with diabetes or prediabetes, agents such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists improve glycemic control and, for several newer agents, show independent cardiovascular and stroke benefit beyond glucose lowering alone.
Anticoagulation for atrial fibrillation: When AFib is identified — either pre-existing or newly detected on extended monitoring — direct oral anticoagulants (DOACs) reduce ischemic stroke risk by roughly 64% versus no anticoagulation, with a substantially better safety profile than warfarin in most patients.
Trial-level relative risk reductions assume near-complete medication-taking, which real-world patients rarely sustain. Population studies consistently show that only 50–60% of secondary-prevention medications are still being taken as prescribed at one year post-stroke, and adherence continues declining thereafter.
The relationship between adherence and benefit is not linear in practice — partial adherence yields disproportionately reduced benefit for several reasons:
• Intermittent statin use allows LDL and inflammatory markers to rebound between doses • Inconsistent antihypertensive dosing produces blood pressure variability, which is itself an independent stroke risk factor distinct from mean blood pressure • Missed anticoagulant doses create dangerous "gap" windows where thromboembolic risk returns rapidly (within 48–72 hours for most DOACs, given their short half-lives)
This is why adherence-support interventions (Stage 4) are not an afterthought but a core, evidence-based component of secondary-prevention protocols.
A meta-analysis of post-stroke statin adherence found that patients in the highest adherence quartile (>80% of prescribed doses taken) had roughly half the recurrent vascular event rate of patients in the lowest quartile (<50%) — even though both groups were prescribed the identical high-intensity regimen.
Pharmacologic therapy alone cannot capture the full modifiable risk. Structured smoking cessation support, regular aerobic exercise, a Mediterranean-style dietary pattern, and sustainable weight management together address risk pathways that no pill fully replaces — endothelial function, systemic inflammation, insulin sensitivity, and thrombotic tendency all respond independently to behavior change.
Smoking roughly doubles ischemic stroke risk through endothelial injury, accelerated atherogenesis, elevated fibrinogen, and enhanced platelet aggregability. Critically, this excess risk is substantially reversible: within 2–5 years of sustained cessation, a former smoker's stroke risk approaches that of a never-smoker — one of the fastest-acting risk reversals in vascular medicine.
Effective cessation support combines behavioral counseling with pharmacotherapy (varenicline, bupropion, or nicotine replacement), which roughly doubles or triples quit rates compared to willpower alone. Post-stroke "teachable moment" counseling, delivered during or immediately after hospitalization, shows measurably higher long-term quit rates than counseling offered at a routine outpatient visit.
Exercise: Regular moderate-intensity aerobic activity (≥150 minutes/week, per AHA/ASA secondary-prevention guidelines) is associated with a 25–30% reduction in recurrent stroke risk in observational cohorts, acting through blood pressure reduction, improved endothelial function, favorable lipid changes, and weight management. Structured cardiac/stroke rehabilitation programs improve both adherence and functional capacity compared to unsupervised advice alone.
Diet: The PREDIMED trial demonstrated that a Mediterranean dietary pattern — emphasizing olive oil, nuts, vegetables, legumes, fish, and reduced red meat/processed food — reduced composite cardiovascular events (including stroke) by roughly 30% compared to a low-fat control diet, one of the largest dietary intervention effects ever demonstrated in a randomized trial. Sodium reduction independently lowers blood pressure and provides an additive benefit.
Weight management: In patients with obesity, even modest sustained weight loss (5–10% of body weight) meaningfully improves blood pressure, insulin sensitivity, and lipid profile — effectively amplifying the benefit of the pharmacologic pillars in Stage 2 rather than acting as an independent fifth pillar.
Lifestyle modification and medication adherence are not competing priorities — they are multiplicative. A patient with excellent medication adherence but a sedentary, high-sodium diet leaves substantial preventable risk on the table, and vice versa. The composite control score in this simulator reflects that interaction.
Knowing what to do is rarely the limiting factor in secondary stroke prevention — sustaining it is. Polypharmacy complexity, out-of-pocket cost, limited health literacy, and gaps in structured follow-up erode adherence over months and years. Each barrier has a matched, evidence-based support intervention that measurably restores adherence rates.
Polypharmacy complexity: A typical post-stroke regimen combines an antiplatelet or anticoagulant, a statin, one or more antihypertensives, and often a glycemic agent — five or more daily medications with different dosing schedules, food interactions, and side-effect profiles. Regimen complexity is one of the strongest independent predictors of nonadherence.
Cost burden: Out-of-pocket costs for brand-name DOACs, newer glycemic agents, and even generic statins can be substantial for uninsured or underinsured patients, leading to dose-skipping or rationing — a pattern strongly associated with recurrent vascular events.
Health literacy: Roughly one in three adults has limited health literacy, and this population carries a disproportionate stroke burden. Complex instructions ("take with food," "avoid with grapefruit," target blood pressure numbers) are frequently misunderstood without teach-back counseling.
Follow-up gaps: Post-discharge follow-up appointments are missed at high rates, particularly in patients with cognitive or motor impairment from the index stroke itself — creating a vicious cycle where the neurological deficit most likely to require support is the same deficit that impedes accessing it.
Care coordination: Dedicated stroke navigators or pharmacist-led transitions-of-care programs reduce 30-day readmission and improve medication reconciliation accuracy, catching errors and barriers before they cause a missed dose.
Reminder systems: SMS text reminders, smartphone apps, and smart pillboxes with adherence tracking produce measurable, reproducible gains in refill and dose-taking rates across multiple randomized trials.
Regimen simplification: Converting to single-pill combination products (e.g., combined antihypertensive classes in one tablet) and aligning dosing to once-daily schedules where clinically appropriate reduces pill burden and consistently improves adherence.
Health-literacy-adapted counseling: Teach-back methods, plain-language written instructions, and multilingual materials measurably improve comprehension and self-management, particularly for blood pressure and glucose self-monitoring targets.
Structured follow-up scheduling: Automated appointment reminders, telehealth options for patients with mobility limitations, and caregiver involvement in scheduling close the follow-up gap that otherwise silently erodes long-term control.
A randomized trial of a multicomponent adherence-support bundle (pillbox + reminders + pharmacist follow-up calls) in post-stroke patients raised 12-month medication adherence by roughly 20 percentage points compared to usual care — translating directly into better blood pressure and lipid control at follow-up.
No single intervention prevents a recurrent stroke on its own — the benefit accrues gradually as blood pressure stabilizes, LDL falls and plaque stabilizes, glycemic control improves, and behavioral changes take hold. Modeled cumulatively, excellent multi-factor adherence can lower relative recurrent stroke risk by up to roughly 80% compared to no secondary prevention at all, though real-world results depend heavily on how consistently that adherence is sustained.
Each risk factor operates through overlapping biological pathways — endothelial dysfunction, atherosclerotic plaque burden, thrombotic tendency, and vascular inflammation. Controlling multiple factors simultaneously does not just remove separate slices of risk; it interrupts feedback loops between them. Lower blood pressure reduces mechanical stress on unstable plaque; lower LDL stabilizes that same plaque; smoking cessation restores endothelial function that blood-pressure control alone cannot fully repair; exercise and diet improve insulin sensitivity, which in turn eases blood pressure control.
This is why multi-factor adherence programs consistently outperform single-factor optimization in outcome trials, and why this simulator models a composite, weighted adherence score rather than crediting either pharmacologic or lifestyle adherence alone.
Recurrent stroke risk is front-loaded, so early, consistent adherence yields disproportionate benefit. Roughly:
• Months 0–3: highest recurrence hazard period; blood pressure and lipid control begin taking effect within weeks, but the cumulative protective effect is still building • Months 3–12: risk factor control stabilizes; if adherence is sustained, recurrence hazard falls substantially from the acute-phase peak • Years 1–5: sustained multi-factor adherence produces the largest absolute risk reduction, as plaque stabilization, smoking-cessation benefit, and behavioral changes reach their fuller protective effect
Adherence that lapses and resumes repeatedly ("adherence gaps") does not simply average out — each lapse re-exposes the patient to elevated risk during the gap window, particularly for anticoagulation and blood pressure control, both of which have relatively short "protective half-lives" after a missed dose.
Illustrative modeling in this simulator: a patient sustaining Excellent composite adherence (medication + lifestyle both consistently high) tracks toward roughly an 80% relative reduction in 5-year recurrent stroke risk, versus minimal reduction for Poor adherence — underscoring that the prescription alone protects no one; sustained adherence is the active ingredient.